Back to Agenda
[Session 7] Development and Management of Strategic Labeling and Risk
Session Chair(s)
Rie Matsui, RPh
Senior Director, Regional Labeling Head for APAC, International Labeling
Pfizer R&D Japan G.K., Japan
Labeling and Pharmacovigilance regulations are rapidly changing and various efforts have been made in the Asian region to adjust to these evolving requirements. Since simultaneous drug development based on MRCTs including the Asian region are increasing, efficient development of patient-centric labeling and risk management plans are clearly a priority. This session will share recent experience on these topics in Asia, and discuss current challenges and future perspectives on the management of labeling and risk management plans from the Asian and global points of view.
Speaker(s)
The End to End Labelling Process
Shimon Yoshida, PhD
Pfizer Inc, United Kingdom
Executive Director, International Labeling Group, Global Regulatory Affairs
Labeling Management from Asia Regional Perspective
Fengyun(Vicky) Han
Johnson & Johnson Pte. Ltd., Singapore
Senior Director, Head of Regulatory Policy for Asia Pacific
Risk Management Plan in Asia
Gao Gao, MD
Pfizer China R&D Center, China
Director and Global Safety Risk Lead, Safety Surveillance and Risk Management
Have an account?